These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37835514)

  • 1. Taxifolin Inhibits the Growth of Non-Small-Cell Lung Cancer via Downregulating Genes Displaying Novel and Robust Associations with Immune Evasion Factors.
    Lin X; Dong Y; Gu Y; Wei F; Peng J; Su Y; Wang Y; Yang C; Neira SV; Kapoor A; Tang D
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade.
    Chi A; He X; Hou L; Nguyen NP; Zhu G; Cameron RB; Lee JM
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.
    Gu Y; Lin X; Dong Y; Wood G; Seidah NG; Werstuck G; Major P; Bonert M; Kapoor A; Tang D
    J Exp Clin Cancer Res; 2023 Jan; 42(1):2. PubMed ID: 36588164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
    Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxifolin Inhibits Breast Cancer Growth by Facilitating CD8+ T Cell Infiltration and Inducing a Novel Set of Genes including Potential Tumor Suppressor Genes in 1q21.3.
    Lin X; Dong Y; Gu Y; Kapoor A; Peng J; Su Y; Wei F; Wang Y; Yang C; Gill A; Neira SV; Tang D
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
    Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
    Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.
    Yang M; Lin C; Wang Y; Chen K; Zhang H; Li W
    Genome Med; 2022 Jul; 14(1):72. PubMed ID: 35799269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in
    Liu D; Benzaquen J; Morris LGT; Ilié M; Hofman P
    Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
    Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. lncRNA PCBP1-AS1 mediated downregulation of ITGAL as a prognostic biomarker in lung adenocarcinoma.
    Wang Q; Xiao G; Li N; Jiang X; Li C
    Aging (Albany NY); 2023 May; 15(10):4510-4523. PubMed ID: 37256932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 14. Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression.
    Xu Y; Xu J; Qiao R; Zhong H; Xia J; Zhong R
    Transl Oncol; 2023 Jul; 33():101671. PubMed ID: 37068401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Escape Mechanisms in Non Small Cell Lung Cancer.
    Anichini A; Perotti VE; Sgambelluri F; Mortarini R
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33276569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma.
    Wang N; Zhu L; Xu X; Yu C; Huang X
    Comput Struct Biotechnol J; 2022; 20():4390-4401. PubMed ID: 36051873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potential target genes of non-small cell lung cancer in response to resveratrol treatment by bioinformatics analysis.
    Gao P; Ren G
    Aging (Albany NY); 2021 Oct; 13(19):23245-23261. PubMed ID: 34633989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments.
    Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L
    J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.